SCHEMBL4128063

SCHEMBL4128063

Fc1cc(OCc2ccccc2)ccc1-c1ccc2c(c1)CCC(N1CCCC1)C2

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 9/20 0.54
CYP2D6 P10635 3/20 0.54
BACE1 P56817 1/20 0.50
HRH1 P35367 1/20 0.44
INSR P06213 2/20 0.42
IGF1R P08069 2/20 0.42
AURKA O14965 1/20 0.42
ROCK2 O75116 1/20 0.42
PAK4 O96013 1/20 0.42
CHEK2 O96017 1/20 0.42
LCK P06239 1/20 0.42
CSF1R P07333 1/20 0.42
LYN P07948 1/20 0.42
FGFR1 P11362 1/20 0.42
RPS6KB1 P23443 1/20 0.42
MARK3 P27448 1/20 0.42
FLT4 P35916 1/20 0.42
KDR P35968 1/20 0.42
FLT3 P36888 1/20 0.42
CSNK1D P48730 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4131332 0.87 HRH3 (0.58) HRH3CYP2D6BACE1HRH1GRIN2B
SCHEMBL4142009 0.86 HRH3 (0.48) HRH3CYP2D6BACE1HRH1GRIN2B
SCHEMBL4142046 0.85 HRH3 (0.56) HRH3CYP2D6BACE1HRH1INSR
SCHEMBL4144748 0.84 HRH3 (0.49) HRH3CYP2D6BACE1HTR1AHTR7
SCHEMBL4135988 0.81 HTR1A (0.49) HRH3HTR1AHTR7GRIN2BFAAH
SCHEMBL4133564 0.75 HTR1A (0.48) HRH3BACE1HTR1AHTR7GRIN2B
SCHEMBL4145755 0.74 HRH3 (0.47) HRH3BACE1HTR1AHTR7GRIN2B
SCHEMBL4145248 0.74 GRIN2B (0.51) HRH3BACE1HTR1AHTR7GRIN2B
SCHEMBL4136395 0.73 HTR2C (0.54) HRH3HTR1AHTR7GRIN2B
SCHEMBL4135788 0.73 HRH3 (0.51) HRH3CYP2D6BACE1HRH1GRIN2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090163482-A1 TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR MCHARDY STANTON FURST 2009-06-25 US claimed
EP-2007749-A2 TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR Pfizer Products Inc. (US) 2008-12-31 EP claimed
WO-2007105053-A2 TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR PFIZER PRODUCTS INC. (US) 2007-09-20 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090163482-A1 TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR HRH3, HRH4, HRH1 HRH3 1/4885CYP2D6 1777/4885BACE1 450/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.